Egypt, the country with the highest prevalence of hepatitis C, is leading the way in treating the disease with revolutionary new drugs deployed at a scale unmatched by its wealthier counterparts. The secret? Savvy negotiating, and systematic deployment of affordably-priced drugs.
By 2015, hepatitis accounted for 7.6% of all deaths in Egypt. But government negotiations with drugmakers dropped the price of a new treatment, and in 2014 Egypt debuted a program that treated to 1.6 million hepatitis C patients in 3 years. That's more than the US and Europe combined during that period. Last year, Egypt followed up with a nationwide screening program seeking out undiagnosed cases.